Search Result

Results for "

procognitive

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (9) Adrenergic Receptor (1) Amyloid-β (1) Carbonic Anhydrase (1) Cholinesterase (ChE) (3) Dopamine Receptor (2) GABA Receptor (1) GPR52 (2) iGluR (3) mAChR (4) mGluR (1) mTOR (2) nAChR (2) Phosphodiesterase (PDE) (1) Reference Standards (3) Tau Protein (1) Trace Amine-associated Receptor (TAAR) (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (1) Neurological Disease (27)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-101787

TP-024 2 Publications Verification FTBMT	GPR52	Neurological Disease
TP-024 (FTBMT), a chemical probe, is a selective GPR52 agonist with an EC₅₀ of 75 nM . TP-024 has antipsychotic and procognitive properties .

HY-120051

Afizagabar 2 Publications Verification S44819; Egis-13529	GABA Receptor	Neurological Disease
Afizagabar (S44819) is a first-in-class, competitive, and selective antagonist at the GABA-binding site of the α5-GABAAR, with an IC₅₀ of 585 nM for α5β2γ2 and a K_i of 66 nM for α5β3γ2. Afizagabar enhances hippocampal synaptic plasticity and exhibits pro-cognitive efficacy .

HY-171844

CX1739	iGluR	Neurological Disease Inflammation/Immunology
CX1739 is an orally active, blood-brain barrier permeable, low-efficacy AMPA-glutamate receptor (AMPAR) potentiator. CX1739 enhances excitatory neurotransmission by potentiating glutamate-induced excitatory currents and promoting in vivo long-term potentiation. CX1739 eliminates amphetamine-induced locomotor activity, reverses opioid-, pentobarbital- and ethanol-induced respiratory depression, and exerts pro-cognitive effects in animals. CX1739 impairs motor function recovery and increases the risk of post-injury complications. CX1739 can be used in research related to attention-deficit/hyperactivity disorder, dementia, respiratory depression and spinal cord injury .

HY-107111

GSK1034702	mAChR	Neurological Disease
GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-13058

ADX-47273 1 Publications Verification	mGluR	Neurological Disease
ADX-47273 is a potent, selective and brain-penetrant mGluR5 positive allosteric modulator (PAM), with an EC₅₀ of 0.17 μM for potentiation of glutamate (50 nM) response. ADX-47273 has antipsychotic and procognitive activities .

HY-109046

Tulrampator 2 Publications Verification CX-1632; S-47445	iGluR mTOR	Neurological Disease
Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .

HY-12700

RO5256390 3 Publications Verification	Trace Amine-associated Receptor (TAAR)	Neurological Disease
RO5256390 is an orally effective trace amine associated receptor 1 (TAAR1) agonist. RO5256390 exhibits pro-cognitive and antidepressant-like properties in rodent and primate models, showing similar brain activation patterns to Olanzapine (HY-14541). RO5256390 blocks compulsive overeating behavior in rats. RO5256390 can inhibit ATP (HY-B2176)-induced TNF secretion in mouse bone marrow-derived macrophages .

HY-14826

Tilivapram AVE8112	Phosphodiesterase (PDE)	Neurological Disease
Tilivapram (AVE8112) is an orally active PDE4 inhibitor with procognitive effects. Tilivapram exhibits in vivo efficacy and improves processing speed and psychomotor speed. Oral administration of tilivapram may induce dose-related adverse reactions such as nausea and dizziness, but transdermal delivery enables slow, controlled elevation of plasma concentrations, thereby significantly reducing gastrointestinal discomfort and dizziness. Tilivapram is applicable to research related to neuropsychiatric disorders .

HY-109118A

Masupirdine mesylate SUVN-502 mesylate	5-HT Receptor	Neurological Disease
Masupirdine mesylate (SUVN-502 mesylate) is a potent, selective, orally active, and brain-penetrating 5-HT₆ receptor antagonist (K_i of 2.04 nM for human 5-HT₆ receptor). Masupirdine mesylate has pro-cognitive effects on all stages of cognition (acquisition, consolidation, and retention), and can reverse Scopolamine (HY-N0296), MK-801 (HY-15084B)-induced and aging-related memory deficits. Masupirdine mesylate can be used in the research of Alzheimer's disease .

HY-118363

Lu AE51090	mAChR	Neurological Disease
Lu AE51090 is selective muscarinic M1 receptor agonist with blood-brain barrier penetration. Lu AE51090 activates human M1 receptor with EC₅₀ of 61 nM, while showing no significant agonism at M2-M5 receptors. Lu AE51090 exerts procognitive effects in mice. Lu AE51090 can be used for the study of Alzheimer’s disease (AD) and cognitive impairment associated with schizophrenia (CIAS) .

HY-14827

Zicronapine Lu 31-130	Dopamine Receptor 5-HT Receptor	Neurological Disease
Zicronapine is an antipsychotic agent with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors .

HY-14827A

Zicronapine fumarate Lu 31-130 fumarate	Dopamine Receptor 5-HT Receptor	Neurological Disease
Zicronapine (Lu 31-130) fumarate is an antipsychotic agent with a strong pro-cognitive effect in animal models and the potential to treat a number of neurological and psychiatric diseases. Zicronapine (Lu 31-130) fumarate has potent antagonistic effects at dopamine D1/D2, and serotonin 5-HT2A receptors .

HY-109118

Masupirdine free base SUVN-502 free base	5-HT Receptor	Neurological Disease
Masupirdine free base (SUVN-502 free base) is a potent, selective, orally active, and brain-penetrating 5-HT₆ receptor antagonist (K_i of 2.04 nM for human 5-HT₆ receptor). Masupirdine free base has pro-cognitive effects on all stages of cognition (acquisition, consolidation, and retention), and can reverse Scopolamine (HY-N0296), MK-801 (HY-15084B)-induced and aging-related memory deficits. Masupirdine free base can be used in the research of Alzheimer's disease .

HY-106400

EGIS 11150	Adrenergic Receptor	Neurological Disease
EGIS 11150 is a adrenergic reporter antagonist that has high affinity for adrenergic α₁, α_2c, 5-HT_2A reporters. EGIS 11150 is an antipsychotic compound with procognitive efficacy .

HY-169163

BChE-IN-36	Carbonic Anhydrase Cholinesterase (ChE)	Neurological Disease
hBChE-IN-4 (compound 40) is a potent hCA activator and BChE inhibitor with K_A values of 266, 76.9, 918, 893, 98.0 nM for hCA I, hCA II, hCA IV, hCA VB, hCA VII, IC₅₀ values of 72.1, 4.2 nM for eeAChE, eqBChE, respectively. hBChE-IN-4 shows no cytotoxicity. hBChE-IN-4 shows potent procognitive effects. hBChE-IN-4 has the potential for the research of neurodegenerative diseases and other neuropsychiatric disorders .

HY-115724

FPPQ	5-HT Receptor	Neurological Disease
FPPQ is a dual-acting 5-HT₃ (K_i = 0.9 nM) and 5-HT₆ (K_i = 3 nM) receptor antagonist with antipsychotic and procognitive properties.

HY-145862

5-HT6/5-HT2AR antagonist-1	5-HT Receptor	Neurological Disease
5-HT6/5-HT2AR antagonist-1 is a potent dual 5-HT₆/5-HT_2AR antagonist with K_i values of 11 nM and 39 nM, respectively .

HY-149776

RGH-560	nAChR	Neurological Disease
RGH-560 (compound 53) shows highly advanced α7 nAChR positive modulator properties and favorable physicochemical features. RGH-560 has robust procognitive in vivo potential. RGH-560 can be used to study Scopolamine (HY-N0296) -induced amnesia in mice .

HY-174381

BChE-IN-41	Cholinesterase (ChE) Amyloid-β Tau Protein	Neurological Disease
BChE-IN-41 is a highly selective Butyrylcholinesterase (BChE) inhibitor (IC₅₀ =12 nM, K_i= 6.6 nM). BChE-IN-41 has high brain penetration with a brain-to-plasma ratio of 9.0. BChE-IN-41 has pro-cognitive effects on mice with AD-like symptoms induced by Scopolamine (HY-N0296) and Aβ_1-42 .

HY-146077

5-HT6/5-HT2A receptor ligand-2	5-HT Receptor	Neurological Disease
5-HT6/5-HT2A receptor ligand-2 (compound 42) is a brain-penetrant dual 5-HT₆/5-HT_2A receptor antagonist, with a K_i of 25 nM and 32 nM, respectively. 5-HT6/5-HT2A receptor ligand-2 shows pro-cognitive properties .

HY-107111A

GSK1034702 hydrochloride	Cholinesterase (ChE) mAChR	Neurological Disease
GSK1034702 hydrochloride is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 hydrochloride activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 hydrochloride can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 hydrochloride can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

HY-163150

5-HT6R antagonist 3	5-HT Receptor	Neurological Disease
5-HT6R antagonist 3 (compound 15) is a potent, selective and brain-penetrant 5-HT6R antagonist with K_i values of 14 nM, 3533 nM, 35 nM, 1449 nM for 5-HT6, 5-HT1A, 5-HT2A, 5-HT7, respectively. 5-HT6R antagonist 3 shows anxiolytic-like and properties neuroprotective and procognitive-like effects. 5-HT6R antagonist 3 has the potential for the research of Alzheimer’s Disease .

HY-109046R

Tulrampator (Standard) CX-1632 (Standard); S-47445 (Standard)	Reference Standards iGluR mTOR	Neurological Disease
Tulrampator (Standard) is the analytical standard of Tulrampator (HY-109046). This product is intended for research and analytical applications. Tulrampator (S-47445) is an orally active selective AMPA receptor modulator. Tulrampator possesses procognitive, enhancing synaptic plasticity, anti-depressant-anxiolytic-like, procognitive and potential neuroprotective properties. Tulrampator can be used for research of alzheimer’s disease and in major depressive disorder .

HY-101787R

TP-024 (Standard) FTBMT (Standard)	Reference Standards GPR52	Neurological Disease
TP-024 (Standard) (FTBMT (Standard)) is the analytical standard of TP-024 (HY-101787). This product is intended for research and analytical applications. TP-024 (FTBMT), a chemical probe, is a selective GPR52 agonist with an EC₅₀ of 75 nM . TP-024 has antipsychotic and procognitive properties .

HY-182695

AS2030680	5-HT Receptor	Neurological Disease Cancer
AS2030680 is a blood-brain barrier-permeable, orally active 5-HT5A receptor antagonist. AS2030680 regulates 5-HT5A-related downstream signaling pathways, reduces the frequency of tumorsphere-initiating cells in breast cancer cells, and exerts procognitive activity in animal models. AS2030680 can be used to study cognitive impairments associated with dementia and schizophrenia, as well as breast cancer .

HY-124057

RO5126946	nAChR	Neurological Disease
RO5126946 is a selective, orally active α7 nAChR allosteric potentiator with EC₅₀ values of 0.06 μM (hα7 nAChR) and 770 nM (α7 nAChR), and it crosses the blood-brain barrier. RO5126946 enhances synaptic transmission and positively modulates GABA-ergic responses by increasing peak current, slowing current decay, and elevating the frequency of spontaneous inhibitory postsynaptic currents, without affecting the recovery of receptors from the desensitized state. RO5126946 not only enhances subthreshold nicotine effects and improves associative learning, but also does not interfere with the original pro-cognitive effects of nicotine. RO5126946 can be used to study cognitive impairments associated with diseases such as Alzheimer's disease and schizophrenia .

HY-107111R

GSK1034702 (Standard)	Reference Standards mAChR	Neurological Disease
GSK1034702 (Standard) is the analytical standard of GSK1034702 (HY-107111). This product is intended for research and analytical applications. GSK1034702 is an orally active and allosteric agonist of M1 mAChR (pEC₅₀=8.1) that can cross the blood-brain barrier. GSK1034702 activates the Gq/11 protein-mediated signaling pathway, enhancing neuronal firing and long-term potentiation (LTP) in the CA1 region of the hippocampus. GSK1034702 can modulate hippocampal function, improve memory encoding in the nicotine withdrawal cognitive dysfunction model, and show pro-cognitive effects in rodents. GSK1034702 can be used for the study of the mechanisms of cognitive impairment diseases such as Alzheimer's disease, and has certain peripheral M receptor activation-related side effects (such as gastrointestinal reactions) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

procognitive

Inhibitors & Agonists